Clearly it is essential to have an organized, experienced team in place. One needs an energetic endoscopist, an aggressive surgeon; a capable anesthesiologist and the rest of the supporting cast to undertake prompt diagnostic procedures, perform major surgery quickly, to provide nutritional support and to carry the patient through the post-operative period and a long term follow-up.
Despite all this praise, Orloffis not perfect. He makes the point that he is using the Child-Turcotte-Campbell system of grading the severity of cirrhosis7, but he is not. In the Campbell modification it is necessary to determine whether the ascites is "easily controlled" or "difficult to control", decisions that require multiple observations. In Orloff Long-term management of variceal bleeding with sclerotherapy is associated with a high risk of rebleeding. In this study, with 7 year follow up, 60% of patients rebleed through sclerotherapy with 43% of the total group failing sclerotherapy. This failure was defined as death from rebleeding or the need for surgery for bleeding. This observation is consistent with other randomized studies in which sclerotherapy has been a treatment option and in which there is long-term follow up (1, 2, 3) . While the greatest risk of rebleeding through sclerotherapy is early in the course--the risk never goes away. In this study the authors do further emphasize that the later rebleeding is frequently from gastric varices or portal hypertensive gastropathy. In contrast, decompressive shunt provides significantly better control of bleeding, which in this study translated to an improved survival. The lessons: i) rebleeding through sclerotherapy is about 50% at 5 years, and ii) prevention of rebleeding is one variable in improving survival.
Liver function and encephalopathy were carefully followed in this study. Quantita-tive liver function measured by galactose elimination capacity and indocyanine green clearance, and hepatic encephalopathy measured by clinical, psychometric and electroencephalographic studies were not significantly different in the two randomized groups. While at first sight one is tempted to say that the disadvantages of rebleeding through sclerotherapy and loss of portal perfusion in some of the shunt patients offset each other, this does not really appear to be the case. No patients had severe disabling encephalopathy, and the quantitative measures of liver function remained good. These data are consistent with our own study comparing DSRS and sclerotherapy which measured quantitative liver function. We showed that patients successfully managed with sclerotherapy, who had no major rebleeding, showed a significant improvement in galactose elimination capacity over the first year1. Lesson: the data in this study show that neither of the randomized therapies significantly accelerate liver failure compared to each other.
What of the high mortality and failure to achieve surgical rescue of patients who failed sclerotherapy in this study? This factor is the major difference between this study and our previously published study .I n the Emory study only one patient randomized to sclerotherapy died as a direct result of rebleeding, and 12 were successfully salvaged by surgical management. In contrast, in the present study 8 
